Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

• Andre De Souza,
• Fabio A. Tavora,
• Devalingam Mahalingam,
• Pamela N. Munster,
• Howard P. Safran,
• Wafik S. El-Deiry,
• Wafik S. El-Deiry,
• Benedito A. Carneiro

Affiliations

Andre De Souza

Division of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United States

Fabio A. Tavora

Argos Laboratory, Fortaleza, Brazil

Devalingam Mahalingam

Division of Hematology/Oncology, Northwestern University, Chicago, IL, United States

Pamela N. Munster

Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States

Howard P. Safran

Division of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United States

Wafik S. El-Deiry

Division of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United States

Wafik S. El-Deiry

Department of Pathology and Laboratory Medicine, Alpert Medical School of Brown University, Providence, RI, United States

Benedito A. Carneiro

Division of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United States